https://www.fool.com/investing/2018/05/18/5-things-abbvie-investors-need-to-know.aspx?source=iedfolrf0000001
May 18, 2018 - AbbVie's top executives answer tough questions about the company's products and pipeline.
0
fool:-390355148202388547
0
https://www.fool.com/investing/2018/05/16/a-huge-decision-is-on-tap-for-this-little-biotech.aspx?source=iedfolrf0000001
May 16, 2018 - A make-it or break-it determination is fast approaching for one tiny clinical-stage company.
0
fool:786469017408552308
0
https://www.fool.com/investing/2018/05/12/is-agenus-inc-agen-a-buy.aspx?source=iedfolrf0000001
May 12, 2018 - This cancer-focused biotech will take plenty of shots on goal in the years ahead.
0
fool:-2168945842835777683
0
https://seekingalpha.com/article/4168094-incyte-incy-q1-2018-results-earnings-call-transcript?source=feed_sector_healthcare
May 01, 2018 - Incyte Corp. (NASDAQ:INCY)Q1 2018 Earnings CallMay 01, 2018 8:00 am ETExecutivesMichael Charles A. Booth - Incyte Corp.Hervé Hoppenot - Incyte Corp.Barry P. Flannelly - Incyte Corp.Steven H. Stein - I
0
sa:2585483459511140016
0
http://www.zacks.com/stock/news/301776/incyte-incy-incurs-loss-in-q1-revenues-miss-estimates?cid=CS-ZC-FT-301776
May 01, 2018 - Incyte (INCY) reported disappointing results for the first quarter wherein the company reported a loss against expectation of earnings and sales too missed estimates.
zc:5143384883530489198
0
http://www.zacks.com/stock/news/301644/incyte-incy-reports-a-loss-in-q1?cid=CS-ZC-FT-301644
May 01, 2018 - Incyte reported a loss in the first quarter while sales also beat estimates.
zc:6261977194418595383
0
http://www.zacks.com/stock/news/301466/drug-stocks-q1-earnings-to-watch-on-may-1-pfe-mrk-more?cid=CS-ZC-FT-301466
Apr 30, 2018 - Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.
zc:7743111819222416674
0
http://www.zacks.com/stock/news/301381/should-you-sell-incyte-incy-before-earnings?cid=CS-ZC-FT-301381
Apr 30, 2018 - Incyte (INCY) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
zc:1395075723672595876
0
http://www.zacks.com/stock/news/301187/can-jafaki-help-incyte-incy-beat-earnings-estimates-in-q1?cid=CS-ZC-FT-301187
Apr 27, 2018 - Incyte (INCY) is likely to beat on earnings when it reports first-quarter results on May 1 driven by strong Jakafi sales.
zc:-3832004224900685863
0
http://www.zacks.com/stock/news/300782/biotech-stock-roundup-prta-down-amgn-revises-view-biib-misses-on-sales?cid=CS-ZC-FT-300782
Apr 25, 2018 - The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
zc:-7250744722252231951
0